Who owns Karyopharm Therapeutics Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of KPTI from SEC Form 13F filings across 95 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 95 institutions disclosed 21.1M shares of Karyopharm Therapeutics Inc. worth $206.4M — about 73% of shares outstanding; the largest disclosed holder is RA CAPITAL MANAGEMENT, L.P.. Source: SEC Form 13F filings, parsed by EvidInvest.
95
13F holders
$206.4M
value, 2026 filers
73%
of shares outstanding (21.1M sh)
33
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of KPTI's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 1.9M | $18.7M | 0.2% | 6.6% | 0.0% |
| 2 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.5M | $14.9M | 0.0% | 5.3% | -15.8% |
| 3 | ACORN CAPITAL ADVISORS, LLC | 1.5M | $14.8M | 4.0% | 5.2% | +427.4% |
| 4 | GOLDMAN SACHS GROUP INC | 1.4M | $13.9M | 0.0% | 4.9% | +50.3% |
| 5 | BlackRock, Inc. | 1.4M | $13.9M | 0.0% | 4.9% | +479.3% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 958,979 | $9.4M | 0.0% | 3.3% | +29.6% |
| 7 | Catalio Capital Management, LP | 940,855 | $9.2M | 1.7% | 3.3% | +4.8% |
| 8 | Avidity Partners Management LP | 924,487 | $9.0M | 1.4% | 3.2% | +99.4% |
| 9 | T. Rowe Price Investment Management, Inc. | 786,309 | $7.7M | 0.0% | 2.7% | -49.0% |
| 10 | TWO SIGMA INVESTMENTS, LP | 695,264 | $6.8M | 0.0% | 2.4% | +359.7% |
| 11 | Kalehua Capital Management LLCNEW | 685,644 | $6.7M | 4.8% | 2.4% | new |
| 12 | NEA Management Company, LLCNEW | 576,780 | $5.6M | 0.4% | 2% | new |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 531,231 | $5.2M | 0.0% | 1.8% | +157.7% |
| 14 | Ghisallo Capital Management LLCNEW | 500,000 | $4.9M | 0.1% | 1.7% | new |
| 15 | Soleus Capital Management, L.P. | 440,000 | $4.3M | 0.1% | 1.5% | 0.0% |
| 16 | UBS Group AG | 353,545 | $3.5M | 0.0% | 1.2% | +82.2% |
| 17 | STATE STREET CORP | 325,991 | $3.2M | 0.0% | 1.1% | +303.7% |
| 18 | Affinity Asset Advisors, LLC | 312,500 | $3.1M | 0.1% | 1.1% | -37.5% |
| 19 | Brevan Howard Capital Management LP | 309,817 | $3.0M | 0.0% | 1.1% | +45.9% |
| 20 | MILLENNIUM MANAGEMENT LLC | 305,676 | $3.0M | 0.0% | 1.1% | -27.3% |
| 21 | Boxer Capital Management, LLC | 302,536 | $3.0M | 0.2% | 1% | 0.0% |
| 22 | Davidson Kempner Capital Management LP | 300,000 | $2.9M | 0.0% | 1% | 0.0% |
| 23 | ACADIAN ASSET MANAGEMENT LLC | 298,997 | $2.9M | 0.0% | 1% | +20.1% |
| 24 | SILVERARC CAPITAL MANAGEMENT, LLCNEW | 297,460 | $2.9M | 0.3% | 1% | new |
| 25 | Eversept Partners, LP | 276,174 | $2.7M | 0.1% | 1% | 0.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.